Narlumosbart

DRUG3 trials

Sponsors

Shanghai JMT-Bio Inc., RenJi Hospital, Fudan University

Conditions

Bone DiseasesGiant Cell Tumor of BoneImmunotherapyMultiple MyelomaNSCLCStereotactic Body Radiation Therapy (SBRT)

Phase 2

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

RecruitingNCT06738160

Fudan UniversityImmunotherapy, NSCLC, Stereotactic Body Radiation Therapy (SBRT)

Start: 2025-02-15End: 2028-12-30Target: 27Updated: 2026-09-11

Phase 3

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Not yet recruitingNCT05813665

Shanghai JMT-Bio Inc.Giant Cell Tumor of Bone

Start: 2023-04-30End: 2028-09-30Target: 146Updated: 2023-04-19

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Not yet recruitingNCT06314698

RenJi HospitalBone Diseases, Multiple Myeloma

Start: 2024-04-01End: 2027-04-30Target: 478Updated: 2024-03-18

Related Papers

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

2024-11-052 citations